AGENDA

THURSDAY, March 7

7:00 a.m. – 7:45 a.m.    Breakfast

7:30 a.m. – 7:45 a.m.    Welcoming Remarks and Announcements

7:45 a.m. – 8:00 a.m.    Exam Studying Tips

8:00 a.m. – 10:00 a.m.    Research Design, Statistics, and Evaluating Oncology Literature
Elyse April MacDonald, PharmD, M.S., BCPS
ACPE Number: 0204-9999-24-904-H01-P*
Application-based: 2.0 contact hours
Objectives:
• Evaluate the oncology literature, including study design, identification of sources of bias, methodology, statistical analysis, and applicability of results to clinical practice for the oncology patient population.
• Interpret the validity and results of various types of oncology studies (e.g., meta-analyses, noninferiority trials).
• Interpret findings from the use of study endpoints (e.g., objective response, time to progression, adverse events, quality of life, overall survival) in oncology research.
• Interpret sensitivity, specificity, positive and negative predictive values, measures of effect, correlation, and regression for an oncology study.

10:00 a.m. – 10:15 a.m.    Break

10:15 a.m. – 11:00 a.m.    Pharmacogenomics in Oncology
Christine M. Walko, PharmD, FCCP, BCOP
ACPE Number: 0204-9999-24-903-H01-P*
Knowledge-based: 0.75 contact hour
Objectives:
• Identify appropriate considerations for genetic interpretation in both the germline and somatic settings utilizing a variety of next generation sequencing techniques.
• Apply the results from germline and somatic genetic testing into therapeutic recommendations based on prognostic, predictive and patient characteristics.
• Recognize the place in therapeutic decision making for companion diagnostic testing.

*See page 11 for more details.
11:00 a.m. – 12:00 p.m.  **Gynecologic Malignancies**  
Alexis R. Jones, PharmD, BCOP, CPP  
ACPE Number: 0204-9999-24-904-H01-P*  
Application-based: 1.0 contact hour  
**Objectives:**  
- Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes of clinical trials and current treatment guidelines for a patient with a gynecologic malignancy.  
- Discuss short- and long-term goals including post-therapy and survivorship, with a patient with a gynecologic malignancy and her caregiver.  
- Select relevant information and provide guidance for the public regarding gynecologic malignancy-related issues (e.g., risk factors, prevention and screening).

12:00 p.m. – 1:15 p.m.  **Lunch (On Own)**  
Participants are invited to bring their lunch back to the ballroom and participate in an interactive Statistics Practice Session with Dr. MacDonald.

1:15 p.m. – 2:45 p.m.  **Adult Acute Leukemias and Myelodysplastic Neoplasms**  
Anthony Perissinotti, PharmD, BCOP  
ACPE Number: 0204-9999-24-903-H01-P*  
Application-based: 1.5 contact hours  
**Objectives:**  
- Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for adults with acute leukemia or myelodysplastic neoplasms.  
- Assess the prognostic impact of relevant cancer-related molecular biology testing for an adult with acute leukemia or myelodysplastic neoplasms.  
- Develop an appropriate plan for preventing, monitoring, and treating adverse reactions from pharmacotherapy for acute leukemia and myelodysplastic neoplasms in an adult, including tumor lysis syndrome, neurotoxicity, differentiation syndrome, and cardiac toxicity from arsenic trioxide, and other agents as appropriate.  
- Determine appropriate pharmacotherapy for acute leukemia or myelodysplastic neoplasms in an adult based on genomic test results.
THURSDAY, March 7 (Continued)

2:45 p.m. – 3:30 p.m.  Upper Gastrointestinal and Hepatocellular Carcinomas
Courtney C. Cavalieri, PharmD, BCOP
ACPE Number: 0204-9999-24-904-H01-P*
Application-based: 0.75 contact hour
Objectives:
• Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with esophageal, gastric, or hepatic malignancies.
• Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticancer agents used for gastrointestinal malignancies.
• Develop an appropriate plan for preventing, monitoring, and treating radiation recall and other complications of radiation therapy.

3:30 p.m. – 3:45 p.m.  Break

3:45 p.m. – 5:15 p.m.  Chronic Leukemias
Karen M. Fancher, PharmD, BCOP
ACPE Number: 0204-9999-24-903-H01-P*
Application-based: 1.5 contact hours
Objectives:
• Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration relevant molecular biology testing, genomic information, efficacy and safety outcomes from clinical trials, and current treatment guidelines for patients with chronic leukemia.
• Develop an appropriate plan for preventing, monitoring, and treating infusion-related reactions from monoclonal antibodies used in the treatment of hematologic malignancies.
• Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for the treatment of cancers, including toxicities from tyrosine kinase inhibitors used to treat hematologic cancers.

*See page 11 for more details.
FRIDAY, March 8

7:00 a.m. – 7:45 a.m. Breakfast

7:30 a.m. – 8:30 a.m. Melanoma and Non-Melanoma Skin Cancers
Ryan Bycroft, PharmD, BCOP
ACPE Number: 0204-9999-24-906-H01-P*
Application-based: 1.0 contact hour

Objectives:
- Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with melanoma or non-melanoma skin cancer.
- Discuss short- and long-term goals, including post-therapy and survivorship, with a patient with melanoma or non-melanoma skin cancer and his or her caregiver.
- Select relevant information and guidance for the public regarding melanoma and non-melanoma skin cancer-related issues (e.g., risk factors, prevention, screening).
- Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with the treatment of melanoma and non-melanoma skin cancers, including thyroid level monitoring for chemotherapy agents, immune-mediated toxicities, and toxicity from BRAF inhibitors.

8:30 a.m. – 10:00 a.m. Multiple Myeloma
Donald C. Moore, PharmD, BCPS, BCOP, DPLA
ACPE Number: 0204-9999-24-905-H01-P*
Application-based: 1.5 contact hours

Objectives:
- Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current guidelines for patients with multiple myeloma.
- Evaluate oncology pharmacy services for compliance with established REMS regulations and standards.
- Develop an appropriate plan for preventing, monitoring, and managing common problems associated with the treatment of cancers, including bone metastases in multiple myeloma patients and thromboembolism, hypercalcemia of malignancy, and spinal cord compression.

*See page 11 for more details.
FRIDAY, March 8 (Continued)

10:00 a.m. – 10:15 a.m. Break

10:15 a.m. – 12:00 p.m. Oncology Practice Management
Christopher Fausel, PharmD, MHA, BCOP
ACPE Number: 0204-9999-24-906-H01-P*
Application-based: 1.75 contact hours
*See page 11 for more details.
Objectives:
• Evaluate oncology pharmacy services for compliance with established regulations, professional practice standards, and procedures for handling, administration, and disposal of hazardous drugs.
• Select quality-improvement activities that enhance the safety and effectiveness of the medication-use processes in oncology patient care.
• Explain methods to optimize medication inventory management for oncology patients.
• Evaluate policies and procedures related to conducting research involving of investigational drugs, including drug management in patients with cancer.

12:00 p.m. – 1:15 p.m. Lunch (On Own)

1:15 p.m. – 2:30 p.m. Lymphomas
Karen M. Fancher, PharmD, BCOP
ACPE Number: 0204-9999-24-906-H01-P*
Application-based: 1.25 contact hours
Objectives:
• Design an appropriate patient-specific treatment, supportive care, and monitoring plan to include effectiveness, toxicities and outcomes, based on the most current guidelines for patients with lymphoma.
• Assess the prognostic impact of relevant cancer-related molecular biology testing.
• Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lymphoma and other cancers, including chemotherapy-induced pulmonary toxicities and extravasation.
FRIDAY, March 8 (Continued)

2:30 p.m. – 5:15 p.m.  Breast Cancer (including a 15-minute break within the session)
Danielle Roman, PharmD, BCOP
ACPE Number: 0204-9999-24-905-H01-P*
Application-based: 2.5 contact hours
Objectives:
• Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with breast cancer.
• Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with breast cancer and her or his caregiver.
• Determine appropriate pharmacotherapy for a patient with breast cancer based on genomic test results.
• Identify appropriate diagnostic and prognostic tests related to breast cancer.
• Select relevant information and guidance for the public regarding breast cancer-related issues (e.g., cancer risk factors, prevention, screening).

*See page 11 for more details.
SATURDAY, March 9

7:00 a.m. – 7:45 a.m.  Breakfast

7:30 a.m. – 8:45 a.m.  Hematopoietic Cell Transplantation
Lauren Ice, PharmD, BCOP, BCPS
ACPE Number: 0204-9999-24-908-H01-P*
Application-based: 1.25 contact hours
Objectives:
• Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current guidelines for patients undergoing hematopoietic cell transplantation (HCT).
• Apply appropriate strategies to prevent and treat toxicity from chemotherapy agents employed in HCT conditioning regimens.
• Create a plan for prevention and management of acute and chronic graft-versus-host disease (GVHD) using appropriate systemic and ancillary therapies.
• Discuss short- and long-term treatment goals, including post-therapy and survivorship, with the patient undergoing HCT and his or her caregiver.

8:45 a.m. – 10:00 a.m.  Prostate Cancer
Brette Conliffe, PharmD, BCOP
ACPE Number: 0204-9999-24-908-H01-P*
Application-based: 1.25 contact hours
Objectives:
• Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with prostate cancer.
• Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with prostate cancer and his caregiver.
• Select relevant information and guidance for the public regarding prostate cancer-related issues (e.g., risk factors, prevention, screening).

10:00 a.m. – 10:15 a.m.  Break

*See page 11 for more details.
SATURDAY, March 9 (Continued)

10:15 a.m. – 12:00 p.m.  Lung Cancer
Janelle Mann, PharmD, BCOP
ACPE Number: 0204-9999-24-907-H01-P*
Application-based: 1.75 contact hours
Objectives:
• Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with lung cancer.
• Select relevant information and guidance for the public regarding lung cancer-related issues (e.g., risk factors, prevention, screening).
• Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lung cancer.
• Develop an appropriate plan for preventing, monitoring, and managing adverse reactions associated with tyrosine kinase inhibitors and mTOR inhibitors.

12:00 p.m. – 1:15 p.m.  Lunch (On Own)

1:15 p.m. – 2:15 p.m.  Bladder, Renal Cell, and Testicular Cancers
John Bossaer, PharmD, BCOP
ACPE Number: 0204-9999-24-907-H01-P*
Application-based: 1.0 contact hour
Objectives:
• Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with bladder, renal cell, or testicular carcinomas.
• Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with bladder, renal cell, or testicular carcinomas and his or her caregiver.
• Develop an appropriate plan for preventing, monitoring, and managing QT interval prolongation associated with antineoplastics and oncology supportive care agents.

*See page 11 for more details.
SATURDAY, March 9 (Continued)

2:15 p.m. – 3:15 p.m.  Head, Neck, Adult Central Nervous System, and Thyroid Cancers
Christine M. Walko, PharmD, FCCP, BCOP
ACPE Number: 0204-9999-24-907-H01-P*
Application-based: 1.0 contact hour
Objectives:
• Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with head, neck, adult central nervous system (CNS), or thyroid cancers.
• Select relevant information and guidance for the public regarding head and neck cancer-related issues (e.g., risk factors, prevention, screening).
• Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with the treatment of cancers including cancer cachexia, mucositis, and xerostomia.

3:15 p.m. – 3:30 p.m.  Break

3:30 p.m. – 4:45 p.m.  Lower Gastrointestinal and Pancreatic Cancers
Courtney C. Cavalieri, PharmD, BCOP
ACPE Number: 0204-9999-24-908-H01-P*
Application-based: 1.25 contact hours
Objectives:
• Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with lower gastrointestinal (GI) or pancreatic cancers.
• Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with lower GI or pancreatic cancers and his or her caregiver.
• Select relevant information and guidance for the public regarding lower GI and pancreatic cancer-related issues (e.g., risk factors, prevention, screening).
• Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lower GI or pancreatic cancers, including chemotherapy-induced diarrhea, hand-foot syndrome, hand foot skin reaction, neurotoxicity from oxaliplatin, and dermatologic toxicities from epidermal growth factor receptor inhibitors.

4:45 p.m. – 4:55 p.m.  Closing Remarks

*See page 11 for more details.
RECORDED-ONLY TOPICS

In addition to the programming presented live, there will be three additional presentations (3 contact hours total) available in an audio-recorded format prior to the live course. The presentations are as follows:

**Adult Sarcomas**
Colleen McCabe, PharmD, BCOP  
ACPE Number: 0204-9999-24-909-H01-P*  
Application-based: 0.75 contact hour

**Objectives:**
- Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for adult patients with sarcoma.
- Adjust treatment and monitoring plans as needed based on the tumor genetics and pharmacokinetics of anticancer and supportive-care agents (e.g., methotrexate).
- Develop an appropriate plan for preventing, monitoring, and managing common problems associated with the treatment of adult patients with cancer, including neurotoxicity from ifosfamide and hemorrhagic cystitis.

**Cancer-related Infectious Diseases**
Jessica Auten, PharmD, BCOP  
ACPE Number: 0204-9999-24-909-H01-P*  
Application-based: 1.0 contact hour

**Objectives:**
- Design an appropriate patient-specific management and monitoring plan to address potential infection-related problems that may arise during and following cancer treatment based on current guidelines for treating cancer-related infectious diseases.
- Discuss short- and long-term treatment goals, including post-therapy, with a patient with cancer-related infectious disease and his or her caregiver.

**Pediatric Malignancies and Supportive Care**
Jennifer Young, PharmD, BCOP  
ACPE Number: 0204-9999-24-909-H01-P  
Application-based: 1.25 contact hours

**Objectives:**
- Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for pediatric patients with cancer.
- Assess the prognostic impact of relevant cancer-related molecular biology testing for a pediatric patient with cancer.
- Discuss with a pediatric patient who has cancer and his or her caregiver the short- and long-term treatment goals, including post-therapy and survivorship.
- Assess the regulatory, ethical, and patient rights issues related to conducting research, including informed consent and confidentiality.

*See page 11 for more details.
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

ACPE credit may be claimed at the end of the live Review and Recertification Course after completing an activity evaluation. ACPE credit is sorted into groups, as follows:

<table>
<thead>
<tr>
<th>GROUP</th>
<th>ACPE Number</th>
<th>Title</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0204-9999-24-903-H01-P</td>
<td>Adult Acute Leukemias and Myelodysplastic Syndromes 1.50</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chronic Leukemias                                                   1.50</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pharmacogenomics in Oncology                                         0.75</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>0204-9999-24-904-H01-P</td>
<td>Research Design, Statistics, and Evaluating Oncology Literature 2.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gynecologic Malignancies                                             1.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Upper Gastrointestinal and Hepatocellular Carcinomas                 0.75</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>0204-9999-24-905-H01-P</td>
<td>Breast Cancer                                                        2.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Multiple Myeloma                                                     2.00</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>0204-9999-24-906-H01-P</td>
<td>Oncology Practice Management                                         2.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lymphomas                                                           1.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Melanoma and Non-Melanoma Skin Cancers                               1.00</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>0204-9999-24-907-H01-P</td>
<td>Lung Cancer                                                          1.75</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Head, Neck, Adult Central Nervous System, and Thyroid Cancers        1.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bladder, Renal, and Testicular Cancers                               1.00</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>0204-9999-24-908-H01-P</td>
<td>Hematopoietic Cell Transplantation                                   1.25</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prostate Cancer                                                      1.25</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lower Gastrointestinal and Pancreatic Cancers                        1.25</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>0204-9999-24-909-H01-P</td>
<td>Pediatric Malignancies and Supportive Care                           1.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cancer-related Infectious Diseases                                   1.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Adult Sarcomas                                                       1.00</td>
<td></td>
</tr>
</tbody>
</table>

*See page 11 for more details.*